First Patients are Vaccinated in IMPRINT, immatics' Pivotal Phase III Trial With IMA901 in Patients With Renal Cell Carcinoma (RCC)

Wednesday, June 15, 2011 1 min read

Key Takeaway: First Patients are Vaccinated in IMPRINT, immatics' Pivotal Phase III Trial With IMA901 in Patients With Renal Cell Carcinoma (RCC)

Full Press Release Details

First Patients are Vaccinated in IMPRINT, immatics' Pivotal Phase III Trial With IMA901 in Patients With Renal Cell Carcinoma (RCC).